A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection

BACKGROUND: Bevacizumab is active in the treatment of metastatic colorectal cancer (mCRC). However, efficacy of bevacizumab has predominantly been evaluated on selected patients with relatively good performance status and minor comorbidities. We evaluated the efficacy and safety of bevacizumab in un...

Descripción completa

Detalles Bibliográficos
Autores principales: Osterlund, Pia, Peltonen, Reetta, Alanko, Tuomo, Bono, Petri, Isoniemi, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085307/
https://www.ncbi.nlm.nih.gov/pubmed/25061319
http://dx.doi.org/10.2147/OTT.S63739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085307/
https://www.ncbi.nlm.nih.gov/pubmed/25061319
http://dx.doi.org/10.2147/OTT.S63739

Ejemplares similares